AI assistant
Sending…
Traws Pharma, Inc. — Director's Dealing 2023
Mar 14, 2023
35199_dirs_2023-03-14_f93ceb59-5263-4343-8d37-05626b6da204.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Onconova Therapeutics, Inc. (ONTX)
CIK: 0001130598
Period of Report: 2023-03-13
Reporting Person: Fruchtman Steven M (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-03-13 | Stock Option (right to purchase) | $0.73 | A | 207000 | Acquired | 2033-03-13 | Common Stock (207000) | Direct |
| 2023-03-13 | Restricted Stock Units | $ | A | 69333 | Acquired | Common Stock (69333) | Direct |
Footnotes
F1: These options vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the following two years.
F2: Each restricted stock unit is convertible into one share of common stock.
F3: These restricted stock units vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34 % on the third anniversary
More from Traws Pharma, Inc.
Annual Report
2026
May 29
Proxy Solicitation & Information Statement
2026
May 29
Proxy Solicitation & Information Statement
2026
May 29
Regulatory Filings
2026
May 27
Regulatory Filings
2026
May 26
Share Issue/Capital Change
2026
May 22
Regulatory Filings
2026
May 15
Interim / Quarterly Report
2026
May 15
Regulatory Filings
2026
May 15
Regulatory Filings
2026
May 8